Ondansetron as an Augmentative Treatment for OCD: What Does the Evidence Say?

Obsessive-Compulsive Disorder (OCD) is often treated with selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT). Despite these interventions, many patients experience only partial relief. This has led researchers to explore augmentation strategies, including the addition of ondansetron, a serotonin 5-HT3 receptor antagonist.

Mechanism of Action

• 5-HT3 antagonism: Ondansetron modulates serotonin in a different way compared to SSRIs. Preclinical studies suggest it may reduce compulsive behaviors by altering serotoninergic and dopaminergic activity in brain regions implicated in OCD, such as the orbitofrontal cortex and basal ganglia.

Evidence from Clinical Trials

1. Shavakhi et al. (2014):
   • Design: Double-blind, randomized controlled trial (RCT).
   • Participants: 40 patients with OCD who had a partial response to fluoxetine.
   • Intervention: Fluoxetine (20–40 mg/day) + placebo vs. fluoxetine + ondansetron (4 mg/day).
   • Results: Significant improvement in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores with ondansetron by week 8.
   • Conclusion: Ondansetron was well-tolerated and effective as an adjunctive treatment.
2. Haghighi et al. (2013):
   • Design: Similar double-blind RCT with 60 patients on fluvoxamine (100–200 mg/day).
   • Results: Patients receiving ondansetron (4 mg/day) showed greater reductions in Y-BOCS scores than those on placebo.
   • Conclusion: Ondansetron enhanced the anti-obsessional effects of SSRIs.
3. Meta-Analysis (Emerging Data):
   • While limited RCTs exist, early analyses highlight ondansetron’s promise, particularly in SSRI partial responders.

Practical Considerations

• Dosage: Typically 4 mg/day in studies.
• Tolerability: Generally well-tolerated, with mild side effects like headache and dizziness reported in trials.
• Population: Evidence supports its use in patients with partial response to SSRIs.

Current Limitations

Sample Sizes: Studies to date have small cohorts, limiting generalizability.

Duration: Most trials span 8–12 weeks, leaving long-term efficacy unclear.

Mechanistic Data: While promising, the precise mechanisms remain speculative.

Clinical Takeaway

Ondansetron appears to be a safe and potentially effective augmentation strategy for patients with OCD who have not achieved full remission on SSRIs alone. While more robust data are needed, its unique mechanism and tolerability make it an intriguing option in treatment-resistant cases.